PLOS Biology Impact Factor

PLOS Biology has a 2024 JCR impact factor of 7.2, Q1 in Biology, ranking 6th out of 107 journals in the category. Published by the Public Library of Science since 2003, it is the flagship biology journal in the PLOS portfolio. The 10% acceptance rate and requirement for broad biological significance place it far closer to Cell Reports or Current Biology than to PLOS ONE.

The CiteScore of 14.9 is notably higher than the 7.2 JIF. Scopus uses a four-year citation window across a broader article set; JCR uses two years. PLOS Biology papers accumulate citations steadily over many years, which the longer window captures better.

The 7.2 JIF reflects a journal that evaluates biological significance strictly, publishes at relatively low volume (around 400-600 articles per year), and occupies a genuine quality tier above mid-range open-access outlets. At the 94th percentile in Biology, this is a more meaningful number than the same IF in a category where citation density is uniformly higher.

The five-year JIF of 7.7 running slightly above the two-year value tells you something about citation pattern: PLOS Biology papers accumulate citations persistently rather than in a burst. Works of broad biological significance tend to keep being cited as fields advance, not just in the two years after publication.

One calibration that matters: PLOS Biology's 7.2 is lower than many readers expect given its editorial selectivity. Cell Reports is at 7.3 with roughly twice the acceptance rate. Current Biology is around 8.9. Nature Communications is at 15.7 with roughly similar acceptance. The IF alone does not capture that PLOS Biology is an editorially demanding journal. The acceptance rate and rejection patterns below tell that story more accurately.

Historical values approximate; 2024 from Clarivate JCR 2024.

The drop from approximately 9.8 in 2023 to 7.2 in 2024 is the most notable recent movement. Two dynamics drive this. At relatively low-volume journals, JIF year-to-year volatility can be substantial because the denominator is small and citation patterns for individual highly-cited papers matter more than at megajournals. Additionally, papers at the highest citation ceilings in biology are increasingly going to Nature family journals instead. The 2024 number reflects real citation counts, not an editorial policy change.

Year-over-year, the 2024 JIF is down from approximately 9.8 in 2023 to 7.2, while the five-year JIF remains higher at 7.7. That gap matters. It suggests that authors should read PLOS Biology as a durable broad-biology venue whose articles may continue accumulating citations beyond the two-year JIF window, not as a journal whose selectivity can be reduced to one annual citation snapshot.

PLOS itself explicitly discourages overreliance on journal-level metrics and points authors toward article-level metrics, timing, acceptance rate, and open-science indicators. For authors, the practical use of the impact factor is comparative: it helps calibrate PLOS Biology against PLOS ONE, Cell Reports, Current Biology, eLife, and Nature Communications. It should not be used as the main reason to submit.

In our analysis of PLOS Biology-bound manuscripts, we see authors use the impact factor in three different ways. The productive use is benchmarking: "Is this journal credible enough for a broad-biology paper with open-access requirements?" The risky use is prestige substitution: "Can a 7.2 JIF make up for a manuscript whose significance is still narrow?" The wrong use is target selection by number alone.

We observe a specific failure pattern on these pages: authors compare PLOS Biology with PLOS ONE only by JIF and APC, then miss the real editorial distinction. PLOS ONE screens for technical soundness; PLOS Biology screens for broad biological significance. That is why a technically strong single-system mechanism paper can be a good PLOS ONE submission and still a weak PLOS Biology submission.

SciRev shows author-reported review experiences, while PLOS publishes its own 2024 timing and acceptance-rate metrics. Read together, those signals support a practical conclusion: the first editorial screen is fast enough that the significance case must be obvious before a reviewer ever sees the paper.

In our pre-submission review work with manuscripts targeting PLOS Biology, three patterns generate the most consistent desk-rejection outcomes. The journal desk-rejects a substantial majority of submissions, with initial decisions averaging 6 days.

Manusights internal analysis of PLOS Biology-bound manuscripts shows that the impact-factor query often hides a journal-fit question. Authors are not really asking whether 7.2 is "good." They are asking whether PLOS Biology is selective enough to justify submission, open enough to satisfy funders, and broad enough to reward a mechanism paper that does not fit Cell Reports or Current Biology.

The answer depends on significance breadth. PLOS Biology's own submission guidance asks authors to explain the scientific question, the key finding, the evidence, field significance, and broader biological or public significance in the cover letter. That set of questions is a better submission test than the JIF.

Editors explicitly ask authors to state what significance the results have for the field and for the broader community. That is the hidden screen behind the impact-factor query. If the manuscript cannot answer those questions without leaning on journal prestige, the impact factor is not helping the submission decision.

Mechanisms without cross-system or cross-organism validation. PLOS Biology's stated criteria require "works of exceptional significance, originality, and relevance in all areas of biological science." In practice, editors evaluate whether findings matter to workers across the relevant field, which means significance needs to be demonstrable beyond a single model system. A paper that characterizes a pathway or phenotype in one cell line or one yeast strain, without genetic validation in a second system or comparative evidence for broader relevance, faces consistent desk rejection. This is the sharpest distinction from PLOS ONE: technical rigor plus a single-system demonstration passes PLOS ONE's bar; it does not pass PLOS Biology's. Authors who have completed rigorous work in one system should either add cross-validation before submitting to PLOS Biology or consider PLOS ONE, eLife, or Cell Reports as more honest targets.

Advance framing that is implicit rather than explicit. Staff editors make initial decisions in about 6 days. In that window, they are asking: what is the specific advance, and why does it matter to biologists outside this subfield? Manuscripts where the advance is stated as a possibility ("these findings may contribute to understanding...") rather than a claim ("here we demonstrate for the first time...") fail at initial screening at a higher rate. The abstract and first paragraph of the introduction need to state the advance explicitly before methodological context. "Our results suggest" is not an advance statement. "We demonstrate that X controls Y through Z, explaining why..." is one. Reviewers at PLOS Biology have flagged this pattern in published review histories as a primary reason for not recommending acceptance.

Incremental mechanistic advances without competitive framing. PLOS Biology publishes 400-600 articles per year and has CiteScore 14.9. The papers it accepts are expected to shift how the field thinks about a problem, not just extend existing models by one experiment. Manuscripts that present a new component in a known pathway, a new interactor in a characterized complex, or a new condition where an established mechanism applies, without a clear statement of what question this resolves or what prior model it overturns, face rejection for insufficient significance. The minimum framing is explicit: what did the field previously think, what does this paper show instead, and what changes as a result? If any of these three patterns match your manuscript, a PLOS Biology framing check identifies whether your significance case, cross-system validation, and advance statement clear the desk before you find out in 6 days.

Last verified: April 2026 against Clarivate JCR 2024 data and PLOS Biology editorial guidelines.

The staff editorial model is worth understanding. PLOS Biology editors are professional editors, not practicing academics, which means they read across all subfields of biology and screen for significance signals that transcend any one subfield's conventions. A paper that any biologist, not just a specialist in that system, would find significant is what they are looking for.

What works: a paper where the discovery changes how a biological principle is understood, not just how one phenomenon is described. The narrative in the introduction should position the work against prior knowledge ("the field believed X because of Y, but this paper shows Z"). Papers where broader significance emerges naturally from the result, rather than being argued for in the discussion, tend to perform better at triage.

What doesn't get said explicitly: PLOS Biology's review process involves 2-3 external reviewers for papers that pass the initial screen. The staff editor reads the reviews and makes an independent judgment on significance. This means a paper can receive favorable technical reviews but still be rejected if the editor judges the significance insufficient for PLOS Biology's scope. A positive reviewer response does not guarantee acceptance at the borderline of the journal's significance threshold.